↓ Skip to main content

Dove Medical Press

Recombinant factor VIII in the management of hemophilia A: current use and future promise

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2009
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
81 Mendeley
Title
Recombinant factor VIII in the management of hemophilia A: current use and future promise
Published in
Therapeutics and Clinical Risk Management, May 2009
DOI 10.2147/tcrm.s4412
Pubmed ID
Authors

Jerry S Powell

Abstract

Hemophilia A is a rare inherited bleeding disorder due to mutation of the gene that encodes the coagulation protein factor VIII. Historically, prior to the availability of treatment with factor VIII preparations, most boys died from uncontrolled bleeding, either spontaneous bleeding or after injury, before reaching 20 years of age. One of the most impressive triumphs of modern medicine is that with current recombinant factor VIII replacement therapy, a boy born in the 21st century with severe hemophilia A can anticipate a normal life expectancy with essentially no permanent complications from bleeding. For severe hemophilia A, current optimal treatment should have two goals: first, to provide sufficient factor VIII to prevent spontaneous bleeding, and second, to provide sufficient factor VIII to have normal coagulation function after any trauma. However, the replacement therapy requires tremendous resources for effective use, and remains extraordinarily expensive. Thus there are opportunities for further advances in therapy for hemophilia A. Two major concerns continue to trouble current optimal treatment approaches: some patients will develop neutralizing antibodies during the first 50 infusions of therapeutic factor VIII, and second, to administer therapeutic factor VIII every other day in young boys often requires placement of a central venous access device, and such use carries the life-threatening risks of infection and thrombosis. Because of the effectiveness of current therapy, any new developments in treatment will require significant concerns for safety, both immediate and in the long term. A number of research groups seek to prolong the biological efficacy of infused recombinant factor VIII. Currently, one such promising development is in the advanced stages of clinical trial. The goals will be to improve further the quality of life of an individual with severe hemophilia A, and to reduce the burden of current treatment strategies on families and medical resources. Hopefully, the hemophilia community will continue to participate actively in the clinical trials needed to address these new challenges.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 3 4%
Brazil 2 2%
India 1 1%
Ukraine 1 1%
United States 1 1%
Unknown 73 90%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 17%
Student > Master 10 12%
Researcher 10 12%
Student > Ph. D. Student 9 11%
Other 5 6%
Other 15 19%
Unknown 18 22%
Readers by discipline Count As %
Medicine and Dentistry 18 22%
Biochemistry, Genetics and Molecular Biology 14 17%
Agricultural and Biological Sciences 11 14%
Nursing and Health Professions 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 14 17%
Unknown 16 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2021.
All research outputs
#7,204,882
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#365
of 1,323 outputs
Outputs of similar age
#32,641
of 104,030 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 6 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 104,030 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.